Valuation : ImmuCell Corporation

Market Cap 89.46M 77.08M 72.98M 66.15M 124M 8.55B 125M 867M 333M 4.35B 336M 329M 13.74B P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 98.85M 85.17M 80.64M 73.09M 137M 9.44B 138M 958M 368M 4.8B 371M 363M 15.18B EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.82%
Yield 2024 *
-
Yield 2025 -
1 day-0.66%
1 week-0.51%
Current month+0.61%
1 month-10.29%
3 months+1.76%
6 months+48.57%
Current year+60.16%
1 week 9.63
Extreme 9.6341
10.02
1 month 9.55
Extreme 9.55
10.72
Current year 5.75
Extreme 5.75
12.1
1 year 4.52
Extreme 4.52
12.1
3 years 3.34
Extreme 3.34
12.1
5 years 3.34
Extreme 3.34
12.1
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 01/11/2025
Director of Finance/CFO 47 07/04/2025
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 01/12/2013
Director/Board Member 61 31/03/2014
Director/Board Member 66 10/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
15/04/26 Free

Chairman

11,933 0.1319%
15/04/26 Free

Director

17,899 0.1979%
15/04/26 Free

Director

11,933 0.1319%
Change 5-day change 1-year change 3-year change Capi.($)
-0.66%-0.51%+66.39%+103.09% 89.46M
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
-0.75%-4.82%+25.46%+87.14% 178B
Average -0.72%-5.23%+26.51%+46.62% 350.49B
Weighted average by Cap. -0.51%-4.42%+30.96%+54.95%

Financials

2024 2025
Net sales 26.49M 22.83M 21.61M 19.59M 36.75M 2.53B 36.94M 257M 98.71M 1.29B 99.5M 97.31M 4.07B 27.64M 23.82M 22.55M 20.44M 38.35M 2.64B 38.54M 268M 103M 1.34B 104M 102M 4.25B
Net income -2.16M -1.86M -1.76M -1.59M -2.99M -206M -3.01M -20.9M -8.04M -105M -8.1M -7.92M -331M -1.04M -896K -848K -769K -1.44M -99.36M -1.45M -10.08M -3.88M -50.55M -3.91M -3.82M -160M
Net Debt 11.34M 9.77M 9.25M 8.39M 15.73M 1.08B 15.81M 110M 42.26M 551M 42.59M 41.66M 1.74B 9.39M 8.09M 7.66M 6.94M 13.02M 897M 13.09M 90.96M 34.98M 456M 35.26M 34.48M 1.44B
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
11/09/26 $9.850 -0.66% 8,103
10/09/26 $9.915 +0.05% 11,261
09/09/26 $9.910 +0.71% 8,501
08/09/26 $9.840 -0.61% 15,550
04/09/26 $9.900 -1.00% 11,696
  1. Stock Market
  2. Stocks
  3. ICCC Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!